Global Depression Treatment Market Set to Skyrocket, Projected to Surpass US$ 16.8 Billion by 2032 | FMI


The release of generic equivalents to drugs used in the treatment of depression will soon provide the impetus for great total market expansion, resulting in a variety of low-cost prescription options for consumers.

Depression Treatment Market

Recent market insights have unveiled a promising future for the global depression treatment market, forecasting significant growth that is expected to exceed the US$ 16.8 billion mark by the year 2032. The industry is set to embark on an impressive trajectory, commencing at US$ 10.1 billion in 2022 and demonstrating a robust Compound Annual Growth Rate (CAGR) of 5.2% over the forecast period.

The findings of a recent comprehensive study underscore the dominance of pharmaceuticals within the depression treatment segment, revealing that drugs captured an astonishing 99.4% of the demand share in 2021. This emphasizes the pivotal role that pharmaceuticals play in addressing depression on a global scale.

Get your PDF Sample Report with Latest Market Information! https://www.futuremarketinsights.com/reports/sample/rep-gb-14687

The anticipated growth in the depression treatment industry is indicative of the increasing awareness and recognition of mental health issues worldwide. As societal attitudes evolve and the stigma surrounding mental health diminishes, there is a growing demand for effective treatment options. This surge in demand is particularly evident in the pharmaceutical sector, where advancements in research and development continue to drive innovation in depression treatment.

Future Market Insights, a leading player in the healthcare industry, is strategically positioned to capitalize on this burgeoning market landscape. With a commitment to pioneering research, development, and the introduction of novel therapies, Future Market Insights is dedicated to revolutionizing the way depression is treated, focusing on enhancing patient outcomes and quality of life.

“Rising awareness regarding mental health coupled with favorable initiatives by the government will propel the global growth of the depression treatment market over the forecast period,” says an FMI analyst.  

Key Takeaways:

  • Lack of specialists as well as associated social stigma may hinder market growth.
  • High prevalence of depressive disorders fuels the market growth in the U.S.
  • Germany’s depression treatment market will expand at 5.3% CAGR. 
  • The depression treatment market in China will grow at a CAGR of 4.8%.
  • By disease, the depression segment is expected to register a CAGR of 5.3%.
  • Based on product, the drugs segment will grow at a CAGR of 5.2%.

Explore The Art of Informed Decision-Making Via Our Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14687

Competitive Landscape:

  • Viatris (Mylan Pharmaceuticals Inc.)
  • Sunovian Pharmaceuticals
  • AbbVie Inc. (Allergan, Inc.)
  • Jubilant Generics Limited
  • Sanis Health Inc.
  • Abbott Laboratories
  • Aurobindo Pharma
  • Torrent Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • (Apotex Holdings, Inc.) Apotex Corporation
  • Alembic Pharmaceuticals Limited

Leading market players are focusing on tactics like mergers and acquisitions to expand their market reach. These organizations are also keen on developing unique treatment approaches to gain a competitive advantage.

More Insights into Depression Treatment Market Report:

According to the latest FMI reports, based on segmentation, hospitals, in terms of distribution channels, are expected to lead the market growth in the next few years. By disease, the major depression episodes segment will grow at a 5.3% CAGR and contribute substantially to the market growth. On the basis of product type, the drugs segment will dominate the market by accounting for almost 99.4% of depression treatment market sales. This subsegment is likely to grow at a CAGR of 5.2% during the forecast period.

Based on region, the depression treatment market in China is likely to exhibit substantial growth during 2022-2032. The country accounted for 43.4% of the target market share in the East Asia region. Better medical infrastructure and increasing healthcare expenditure drive regional market growth. Countries like Germany and the United States are also anticipated to undergo notable growth over the forecast period.

Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-14687

Key Segments Covered In Depression Treatment Industry Research:

By Products:

  • Drugs
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Citalopram
      • Escitalopram
      • Fluoxetine
      • Fluvoxamine
      • Paroxetine
      • Sertraline
    • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
      • Desvenlafaxine succinate
      • Duloxetine
      • Levomilnacipran
      • Venlafaxine
    • Bupropion
    • Mirtazapine
    • Monoamine oxidase inhibitors (MAOIs)
      • Phenelzine
      • Tranylcypromine
    • Antipsychotics
      • Lithium carbonate
      • Aripiprazole
      • Brexipiprazole
      • Quetiapine
    • Trazodone
    • Others
  • TMS Devices
    • rTMS Devices
    • dTMS Devices

By Disease:

  • Major Depression
  • Persistent Depressive Disorder
  • Bipolar Disorder
  • Seasonal Affective Disorder (SAD)
  • Postpartum Depression
  • Premenstrual Dysphoric Disorder (PDD)
  • Situational Depression
  • Atypical Depression
  • Treatment-Resistant Depression

By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • e-commerce
  • Specialty Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

About Future Market Insights

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market.

Contact Information

Future Market Insights

Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware
19713
USA
Phone : +1-845-579-5705
View website

Published in

Health , Business

Published on

Feb 13, 2024

Social Links